MX2017016331A - Sales de ácido graso de glicopirronio y métodos para elaborar las mismas. - Google Patents

Sales de ácido graso de glicopirronio y métodos para elaborar las mismas.

Info

Publication number
MX2017016331A
MX2017016331A MX2017016331A MX2017016331A MX2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A MX 2017016331 A MX2017016331 A MX 2017016331A
Authority
MX
Mexico
Prior art keywords
fatty acid
glycopyrronium
methods
acid salts
excess
Prior art date
Application number
MX2017016331A
Other languages
English (en)
Other versions
MX389992B (es
Inventor
Itute MOBELE Bingidimi
Karl Liu Xuejun
Goud Puppali Satish
Eisenreich Emerich
A Rich Steven
Original Assignee
Qaam Pharmaceuticals Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qaam Pharmaceuticals Llc filed Critical Qaam Pharmaceuticals Llc
Publication of MX2017016331A publication Critical patent/MX2017016331A/es
Publication of MX389992B publication Critical patent/MX389992B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/03—Monocarboxylic acids
    • C07C57/12—Straight chain carboxylic acids containing eighteen carbon atoms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/96—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation using ion-exchange
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/884—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds
    • G01N2030/8854—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample organic compounds involving hydrocarbons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/88—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86
    • G01N2030/8809—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample
    • G01N2030/8868—Integrated analysis systems specially adapted therefor, not covered by a single one of the groups G01N30/04 - G01N30/86 analysis specially adapted for the sample elemental analysis, e.g. isotope dilution analysis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se han desarrollado nuevas sales de ácido graso de glicopirronio. Las condiciones de reacción bi-fásicas permiten las reacciones de intercambio de contraión deseadas entre bromuro de glicopirronio y sales de ácido graso de metales alcalinos y metales alcalinotérreos en métodos para formar sales de ácido graso de glicopirronio. En modalidades preferidas, un exceso del ácido graso libre en la mezcla de reacción estabiliza la sal de ácido graso de glicopirronio y reduce la formación de la impureza, Ácido A. En algunas modalidades preferidas, entre 0.2 y 1.2 equivalentes molares de ácido graso libre en exceso se adiciona a la mezcla de reacción. En otra modalidad, aproximadamente 1.2 equivalentes molares de ácido graso libre en exceso se adiciona a la mezcla de reacción.
MX2017016331A 2015-06-15 2016-06-06 Sales de ácido graso de glicopirronio y métodos para elaborar las mismas MX389992B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562175737P 2015-06-15 2015-06-15
PCT/US2016/035967 WO2016204998A1 (en) 2015-06-15 2016-06-06 Glycopyrronium fatty acid salts and methods of making same

Publications (2)

Publication Number Publication Date
MX2017016331A true MX2017016331A (es) 2018-09-05
MX389992B MX389992B (es) 2025-03-20

Family

ID=57546015

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017016331A MX389992B (es) 2015-06-15 2016-06-06 Sales de ácido graso de glicopirronio y métodos para elaborar las mismas

Country Status (11)

Country Link
US (1) US10519109B2 (es)
EP (1) EP3307250B1 (es)
JP (1) JP6910069B2 (es)
KR (1) KR102708826B1 (es)
CN (1) CN108024967B (es)
AU (1) AU2016279798B2 (es)
CA (1) CA2989579C (es)
ES (1) ES2942176T3 (es)
MA (1) MA43047A (es)
MX (1) MX389992B (es)
WO (1) WO2016204998A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018167776A1 (en) 2017-03-12 2018-09-20 Sol-Gel Technologies Ltd. Process for the preparation of glycopyrrolate tosylate
CN109884205A (zh) * 2019-03-12 2019-06-14 康诚科瑞医药研发（武汉）有限公司 一种血浆中曲司氯铵的定量检测方法
KR20200129895A (ko) 2019-05-10 2020-11-18 오남주 스마트 태양광 파고라
TW202245748A (zh) 2021-02-05 2022-12-01 日商三和化學研究所股份有限公司 包含吡咯醣･水楊酸鹽之藥品

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892944A (en) 1987-05-13 1990-01-09 Mitsubishi Petrochemical Co., Ltd. Process for producing quaternary salts
JPH03135978A (ja) 1989-08-08 1991-06-10 Merck Sharp & Dohme Ltd 置換ピリジン、その製法、処方並びに痴呆症における使用法
US5861431A (en) 1995-06-07 1999-01-19 Iotek, Inc. Incontinence treatment
EP0932401A1 (en) 1996-07-01 1999-08-04 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
WO1998000133A1 (en) 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (s,s)-glycopyrrolate
US6255502B1 (en) 1996-07-11 2001-07-03 Farmarc Nederland B.V. Pharmaceutical composition containing acid addition salt of basic drug
EP1235818A4 (en) * 1999-10-15 2005-01-19 Danisco Cultor America Inc DIRECT ESTERIFICATION PROCESS OF SORBITOL WITH FATTY ACIDS
GB0008660D0 (en) * 2000-04-07 2000-05-31 Arakis Ltd The treatment of respiratory diseases
EP2283817B1 (en) 2000-11-30 2016-05-18 Vectura Limited Method of making particles for use in a pharmaceutical composition
WO2004034963A2 (en) 2002-05-17 2004-04-29 Eisai Co., Ltd. Methods and compositions using cholinesterase inhibitors
JP2004083456A (ja) * 2002-08-26 2004-03-18 Fuji Photo Film Co Ltd ジアゾニウム塩の製造方法
US7635709B2 (en) 2002-09-26 2009-12-22 The United States Of America As Represented By The Department Of Veterans Affairs Compositions and methods for bowel care in individuals with chronic intestinal pseudo-obstruction
WO2005003108A1 (ja) * 2003-07-01 2005-01-13 Otsuka Chemical Co., Ltd. 第４級アンモニウム塩および電解質並びに電気化学デバイス
US7091236B1 (en) 2003-08-20 2006-08-15 Sciele Pharma, Inc. Method for increasing the bioavailability of glycopyrrolate
EP1616567A1 (en) * 2004-07-16 2006-01-18 Boehringer Ingelheim Pharma GmbH & Co.KG Medicaments for inhalation comprising PDE IV inhibitors and glycopyrrolate salts
EP1814558B1 (en) 2004-11-01 2010-12-15 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
BRPI0519481A2 (pt) * 2004-12-27 2009-02-03 Beiersdorf Ag glicopirrolato em preparaÇÕes cosmÉticas
WO2006100453A1 (en) * 2005-03-24 2006-09-28 Sosei R & D Ltd. Glycopyrronium salts and their therapeutic use
JP2007090557A (ja) * 2005-09-27 2007-04-12 Fujifilm Corp 光学フィルムの製造方法、光学フィルム並びに画像表示装置
BRPI0715054A2 (pt) * 2006-07-28 2013-05-28 Biograde Hong Kong Pty Ltda mÉtodo para preparar uma composiÇço de polÍmero biodegradÁvel, mistura padrço, mÉtodo para preparar a mesma, e, composiÇço de polÍmero biodegradÁvel
WO2008019070A2 (en) * 2006-08-04 2008-02-14 Ebrahim Versi Pharmaceutical compositions of trospium for treating smooth muscle hyperactivity disorders
US8097633B2 (en) 2006-11-15 2012-01-17 Rich Steven A Uses for quaternary ammonium anticholinergic muscarinic receptor antagonists in patients being treated for cognitive impairment or acute delirium
US9034890B2 (en) 2006-11-15 2015-05-19 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
US8969402B2 (en) 2006-11-15 2015-03-03 Steven A. Rich Combined acetylcholinesterase inhibitor and quaternary ammonium antimuscarinic therapy to alter progression of cognitive diseases
WO2009052353A2 (en) 2007-10-17 2009-04-23 Dr. Reddy's Laboratories Ltd. Trospium pharmaceutical formulations
US20110201597A1 (en) 2008-03-27 2011-08-18 Chase Thomas N Method and composition for treating alzheimer-type dementia
EP4088717A1 (en) 2008-03-27 2022-11-16 Chase Pharmaceuticals Corporation Use and composition for treating dementia
JP4621783B2 (ja) * 2008-03-31 2011-01-26 株式会社日本触媒 フルオロスルホニルイミド類およびその製造方法
WO2009153886A1 (ja) * 2008-06-20 2009-12-23 旭化成ケミカルズ株式会社 α－ヒドロキシ酸の製造方法
SI3330255T1 (sl) * 2009-03-20 2021-03-31 Vertex Pharmaceuticals Incorporated Postopek izdelave regulatorja transmembranske prevodnosti pri cistični fibrozi
JP2011246429A (ja) * 2009-06-26 2011-12-08 Idemitsu Kosan Co Ltd アダマンチル基を有する第４級アンモニウム塩の製造方法
EP2478099B1 (en) 2009-09-18 2019-06-05 Chase Pharmaceuticals Corporation Combination for treating alzheimer-type dementia
WO2011157536A1 (en) * 2010-06-14 2011-12-22 Chiesi Farmaceutici S.P.A. Process for the preparation of glycopyrronium chloride
CN103534867B (zh) 2011-06-17 2017-04-12 流体公司 含有磺酸根离子的离子液体
JP5885459B2 (ja) * 2011-10-21 2016-03-15 Ｋｊケミカルズ株式会社 非水溶性イオン性ビニルモノマーの製造方法及びそれからなる帯電防止剤と帯電防止組成物
JP2013227247A (ja) * 2012-04-25 2013-11-07 Kohjin Holdings Co Ltd 非水溶性イオン性ビニルモノマーの製造方法及びそれからなる帯電防止剤と帯電防止組成物
WO2014091384A2 (en) * 2012-12-12 2014-06-19 Mahesh Kandula Compositions and methods for the treatment of mucositis

Also Published As

Publication number Publication date
WO2016204998A1 (en) 2016-12-22
JP6910069B2 (ja) 2021-07-28
EP3307250A4 (en) 2018-08-08
US20180179156A1 (en) 2018-06-28
EP3307250A1 (en) 2018-04-18
US10519109B2 (en) 2019-12-31
CN108024967B (zh) 2021-12-21
CA2989579A1 (en) 2016-12-22
KR102708826B1 (ko) 2024-09-25
AU2016279798A1 (en) 2018-01-18
CA2989579C (en) 2024-09-10
MA43047A (fr) 2018-08-08
AU2016279798B2 (en) 2021-07-08
MX389992B (es) 2025-03-20
JP2018519289A (ja) 2018-07-19
EP3307250B1 (en) 2022-11-23
ES2942176T3 (es) 2023-05-30
CN108024967A (zh) 2018-05-11
KR20180037947A (ko) 2018-04-13

Similar Documents

Publication Publication Date Title
CU20200004A7 (es) Compuestos para tratar afecciones asociadas con la actividad nlrp
MX389992B (es) Sales de ácido graso de glicopirronio y métodos para elaborar las mismas
CY1125677T1 (el) Αλατα νατριου 5-βρωμο-2-(αλφα- υδροξυπεντυλο)βενζοϊκου οξεος σε διαφορετικες κρυσταλλικες μορφες, και μεθοδος παρασκευησαυτων
MX358006B (es) Catalizador de reformado de vapor y metodo para la fabricacion del mismo.
AR092500A1 (es) Solucion de limpieza de colon
MX2018013566A (es) Aparato electroquimico para producir desinfectante.
PE20170897A1 (es) Sintesis de copanlisib y su sal diclorhidrato
AR099434A1 (es) Proceso para la elaboración de derivados de pirimidin sulfamida
UY35009A (es) Composiciones y métodos para mejorar la compatibilidad de sales herbicidas hidrosolubles
AR071060A1 (es) Proceso para la preparacion de betainas
ES2530973T3 (es) Composición de encolado para lana mineral que incluye un azúcar no reductor y una sal metálica de ácido inorgánico, y productos aislantes obtenidos
MX2021000611A (es) Una sal de xinafoato de un compuesto inhibidor de jak.
PH12016500913A1 (en) Soap bar
AR094253A1 (es) Composiciones acuosas de cloquintocet-mexilo de temperatura estable
MX391896B (es) Profármacos de fósforo de estimuladores de guanilato ciclasa soluble (sgc).
BR112018013424A2 (pt) processo para preparação de 1,1,3-trioxo-1,2-benzotiazol-6-carboxamida
EA201990093A1 (ru) Двухкомпонентная композиция
PY1340431A (es) Composiciones y métodos para mejorar la compatibilidad de sales herbicidas hidrosolubles
MX2020003639A (es) Metodo para la conversion mejorada de sales de taurina a alquiltaurato amidas.
PL420099A1 (pl) Sposób produkcji kwasu alfa-ketoglutarowego (AKG) z jednoskładnikowych roztworów wodnych
AR080193A1 (es) Tratamiento de aguas residuales que contienen acidos fluorados o sus sales
AR091863A1 (es) Procedimiento para la preparacion de isobutilidin diurea
CL2008002751A1 (es) Metodos para preparar carbonato de amonio cuaternario, donde se combina bromuro de amonio cuaternario, hidroxido metalico y solvente para formar hidroxido de amonio cuaternario, y combinar con co2 para producir carbonato de amonio cuaternario; preparacion de solucion acuosa.
AR105955A1 (es) Método para producir una piridinacarboxamida
AR093946A1 (es) Un proceso mejorado para el aislamiento del acido 4-amino-3-cloro-6-(4-cloro-2-fluor-3-metoxi-fenil)piridina-2-carboxilico